Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma,

뉴스 본문을 불러오고 있어요.

Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma, | 웨이프 WAPE

Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma,

기사 요약

관련 종목

댓글 —